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Abstract
Background: Women may have incomplete understanding of a breast cancer diagnosis, leading to inaccurate
reporting in epidemiological studies. However, it is not feasible to obtain consent for medical records from all
women participating in a study. Therefore, it is important to determine how well self-reported breast cancer
characteristics correspond with what is found in medical records, but few studies have evaluated agreement
of self-reported breast cancer characteristics with abstracted medical records.
Methods: We calculated the positive predictive value (PPV) of self-reports compared to medical records and
explored whether participant characteristics may have influenced reporting accuracy. We analyzed data from
2518 reported breast cancer cases from the Sister Study, a large nationwide cohort of women with a family
history of breast cancer.
Results: Medical records or pathology reports were obtained for 2066 of 2518 (82%) women who reported incident
breast cancer. Breast cancer was confirmed for over 99% (n = 2054) of women with medical records. Confirmation
rates were high for invasive, ductal, hormone receptor positive, and HER2 negative breast cancers, with little
variation by race/ethnicity or age. Self-reported in situ breast cancer had a lower PPV (64.2%), with medical records
showing invasive breast cancer instead, especially for older and Hispanic women. Hormone receptor (ER and PR)
negative and HER2 positive self-reports had lower PPVs (83.0%, 71.6%, and 66.1% respectively). Hispanic women
and women ages 65 or older at diagnosis were less able to accurately report breast cancer stage, excluding stage I.
Conclusions: Accuracy of reporting overall breast cancer and common subtypes is high. Despite having a family
history of breast cancer and voluntarily enrolling in a study evaluating breast cancer risk factors, participants may
have greater difficulty distinguishing between in situ and invasive breast cancer and may less accurately report
other less common subtypes. Discrepancies may reflect women’s poor understanding of information conveyed
by health care providers or lack of consistent terminology used to describe subtypes.
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Background
Medical records, including pathology reports, are consid-
ered the gold standard for cancer diagnostic information.
However, it is not always feasible in epidemiological stud-
ies of breast cancer to obtain consent for medical records
from all participants. Sociodemographic factors may affect
whether women provide consent for medical records and
may also be correlated with both potential breast cancer
risk factors under investigation and accuracy of self-
reports. Excluding women who do not provide consent
for medical records may result in spurious or biased asso-
ciations with potential breast cancer risk factors. Hence, it
is important to ascertain how well self-reported informa-
tion on breast cancer characteristics approximates what
would have been found in the medical records. Further-
more, disagreement between self-reported breast cancer
data and medical records may indicate women’s lack of
understanding regarding characteristics of their breast
cancer diagnosis, which may have implications for treat-
ment, medical compliance and follow-up, and prognosis.
Few studies have evaluated agreement of self-reported
breast cancer characteristics with abstracted medical re-
cords [1–4], with most largely focusing on agreement for
breast cancer treatment [1–3]. Using data from the Breast
Cancer Family Registry, Phillips, et al. evaluated the agree-
ment for stage at diagnosis and found that women often
over-estimated disease severity, with women at lower
stages reporting a higher stage at diagnosis [1]. In an Aus-
tralian cohort study, which compared self-reports on hor-
mone receptor status for invasive breast cancer cases to
data from pathology reports, older age at diagnosis and
lower education were associated with lower agreement in
hormone receptor status, but the number of women with
hormone receptor negative breast cancer was limited [4].
Other studies have evaluated the concordance between
cancer self-reports and cancer registry data for breast and
other cancer types [5–8], with some studies focusing on
breast cancer characteristics such as hormone receptor
status [7] and treatment [9, 10]. In a recent population-
based cohort sample of 500 breast cancer cases in
California, self-reported data were compared with data
from the state cancer registry. The accuracy of report-
ing for breast cancer characteristics was poor, especially
for minority women, potentially contributing to racial
disparities in breast cancer treatment adherence and
outcomes [11].
In order to address how well self-reported breast can-
cer characteristics accurately depict what is found in the
medical record, we evaluated agreement between infor-
mation from self-reports and medical records for a wide
range of breast cancer characteristics. Data were col-
lected from incident breast cancer cases that developed
within the Sister Study, a large nationwide cohort of
women with a family history of breast cancer.
Methods
Study population
The Sister Study is a large prospective cohort study de-
signed to investigate environmental and genetic risk fac-
tors for breast cancer. The study enrolled 50,884 US and
Puerto Rican women who were ages 35 to 74 between
2003 and 2009. Enrollment criteria included no previous
diagnosis of breast cancer and having a sister who had
been diagnosed with breast cancer. This research was ap-
proved by the Institutional Review Boards of the National
Institute of Environmental Health Sciences, NIH, and the
Copernicus Group; all participants provided written in-
formed consent. At enrollment, participants completed
computer-assisted telephone interviews that assessed
demographics, medical history, and potential risk factors
for breast cancer and other health conditions.
Incident breast cancer diagnoses were reported via par-
ticipant telephone calls, e-mails, or correspondence with
the study office or on follow-up questionnaires completed
by web, mail, or telephone, including brief annual health
updates and more detailed follow-up questionnaires every
two to three years. Response rates for follow-up question-
naires are high at over 90%. For all participants who have
been reported deceased or who have not completed any
recent study activities, regularly scheduled linkages with
the National Death Index (NDI) Plus are carried out to
identify any breast cancer diagnoses that may have been
missed.
Breast cancer assessment
Women who reported a breast cancer diagnosis were
asked to mail in a copy of their diagnostic pathology
report if they had it. Approximately six months post-
diagnosis (or one month after initial self-report if re-
ported more than six months post-diagnosis), women
were asked to complete a breast cancer follow-up
questionnaire that asked for specific diagnostic and
treatment information. Median time from diagnosis to
completion of the breast cancer follow-up question-
naire was approximately 11 months. This follow-up
questionnaire was initially administered exclusively by
telephone, but a self-administered mail version was
later developed. Revision of the breast cancer follow-up
questionnaire was also done over time (four versions)
to reduce participant burden and to capture details of
greatest interest for researchers, which were considered
to be reportable by participants. All versions of the
breast cancer follow-up questionnaire are available on-
line [12]. In addition, women were asked to authorize
release of their medical records for more detailed infor-
mation about their diagnosis and treatment.
Breast cancer characteristics assessed in the breast can-
cer follow-up questionnaire and abstracted from medical
records include the diagnosis date, tumor invasiveness
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(any invasive or in situ only), tumor type (ductal or lobu-
lar), hormone receptor status (estrogen and progesterone
receptors, ER and PR respectively), and human epidermal
growth factor receptor 2 (HER2) status. Medical record
abstractionists generally had access to the entire medical
record related to the breast cancer diagnosis including the
surgical pathology reports. There was 100% quality con-
trol done on all breast cancer record abstractions in which
every record was abstracted by a second reviewer, and any
discrepancies were adjudicated with further review. For
the earliest version of the breast cancer follow-up ques-
tionnaire, the characteristics of each tumor were asked
whereas the later versions asked characteristics of the
diagnosis. The latter two versions also added definitions of
breast cancer terminology for key characteristics such as
invasiveness, tumor type, hormone receptors, and staging.
For invasiveness analyses, we considered participants who
had both invasive and in situ tumors abstracted from the
pathological report as having invasive disease. For tumor
type (ductal or lobular), follow-up questionnaires provided
the option of selecting “both” if applicable, but versions
2–4, which focused on the overall diagnostic characteris-
tics, did not specifically ask whether individual tumors
were mixed ductal/lobular histology or whether women
had both ductal and lobular tumors. Therefore, we com-
bined self-reports of ductal only and “both” (ductal and
lobular) for analyses, and self-reported ductal cancer was
considered confirmed if the abstracted tumor type from
the pathology report indicated ductal only, mixed ductal/
lobular histology, or multiple ductal and lobular tumors.
ER and PR status reported as borderline by participant
or medical record was considered positive, whereas bor-
derline HER2 results were considered as unknown [13].
From the medical record, ER and PR status was typically
assessed from the maximum immunohistochemistry per-
centage (with ER/PR positivity corresponding to ≥1%
staining), or less frequently from laboratory documenta-
tion for the RT-PCR assay, and HER2 status was assessed
from immunohistochemistry (0 and 1+/ not overex-
pressed, 2+/ equivocal, and 3+/ overexpressed) or based
on relevant laboratory documentation from other assays
(including FISH/CISH/DISH/SISH/RT-PCR). Tumor size,
spread to regional lymph nodes, and distant metastases at
breast cancer diagnosis were asked in the first two ver-
sions of the breast cancer follow-up questionnaire (49% of
medically confirmed cases) and also abstracted from med-
ical records to calculate self-reported and medical record
stage based on the 7th edition of the American Joint Com-
mittee on Cancer (AJCC) TNM Breast Cancer Staging al-
gorithm. Staging elements abstracted from the medical
records were based on the surgical pathology report for
tumor size and lymph node(s) spread and the imaging
from the metastatic work-up for distant metastases. A few
women who reported in situ cancer but also reported
spread to regional or distant lymph nodes were considered
invasive cancer and assigned the appropriate stage based
on details provided; these changes were made prior to
comparison with medical records. For the two most recent
versions of the breast cancer follow-up questionnaire
(51% of medically confirmed cases), we did not ask about
tumor size, as women were less able to report this charac-
teristic. Hence, self-reported stage at diagnosis was not
calculated, but instead we directly asked women their
stage at diagnosis.
We included 2518 incident cases who reported a
diagnosis with any type of invasive or in situ breast can-
cer as of July 1, 2014, and we had NDI Plus linkage data
for women with breast cancer as a cause of death or
contributing condition for deaths through December
31, 2011 (Sister Study Data Release 4.0). We obtained
medical records or pathology reports for 2066 reported
cases. For analyses of breast cancer characteristics, we
excluded the 12 women whose medical records indi-
cated that they had a noncancerous benign breast con-
dition as well as 43 cases who did not complete the
breast cancer follow-up questionnaire and 3 cases
where the participant reported on a different breast
cancer diagnostic event than the one captured in her
medical records (n = 2008).
Statistical analysis
We described the frequency distribution of selected
characteristics in women with medical record confirm-
ation of breast cancer (n = 2054) and those without
medical records (n = 452), stratified by race/ethnicity
(non-Hispanic white, non-Hispanic black, Hispanic,
other). We calculated the positive predictive value (PPV),
which represents the percent of self-reports confirmed by
medical records, for overall breast cancer diagnosis and
for the following diagnostic characteristics: invasiveness,
tumor type, stage, and hormone receptor and HER2
status. For hormone receptor and HER2 status analyses,
we restricted to medically-confirmed invasive cases as
these assays are not consistently performed for in situ
cancers. We stratified on race/ethnicity, age at diagnosis,
education, degree of family history, and completed version
of the breast cancer follow-up questionnaire to describe
whether the positive predictive values varied according to
these factors. Women with “other” race/ethnicity (n = 56)
are not shown for analyses stratified by race/ethnicity.
Analyses were performed using SAS version 9.3 (SAS In-
stitute Inc., Cary, NC).
Results
Overall, 82.0% of women with self-reported breast cancer
provided medical records or pathology reports, and all but
12 were confirmed by medical records as either invasive
or in situ breast cancer (PPV = 99.4%). Furthermore, only
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two women who did not report breast cancer during study
follow-up were found through NDI Plus record linkage to
have had breast cancer.
Table 1 depicts those with breast cancer confirmed
by medical records versus those without medical re-
cords stratified by race/ethnicity. Women without
medical records were more often non-Hispanic black
as compared to those with breast cancer confirmed by
medical records (15% vs 6%). Non-Hispanic white
women with medical records to confirm their diagno-
sis and those without medical records were similar in
age and menopausal status at diagnosis, education,
and extent of breast cancer family history. Slightly
more non-Hispanic whites with medical records to
confirm their diagnosis reported being married and
having a higher household income than those without
medical records. However, among non-Hispanic blacks,
those with medical records to confirm their diagnosis
were more often at least 60 years of age or postmeno-
pausal at diagnosis compared to those without medical re-
cords. They also more often had a bachelor’s or graduate
degree, were single, and had a lower household income
than non-Hispanic blacks without medical records.
Exploration of differences among Hispanic women was
limited due to smaller numbers although there appeared
to be greater frequency of Hispanics with medical records
who were younger and premenopausal at diagnosis than
those without medical records.
The PPVs for self-reported invasive breast cancer
(99.3%) and any ductal cancer (98.9%) were very high
(Table 2). However, the PPVs were lower for in situ
(64.2%) and lobular only (75.7%) cancer, possibly
Table 1 Characteristics of women with incident breast cancer with medical record confirmation and without medical records,
stratified by race/ethnicity, Sister Study 2003-2014a
Medically confirmed (n = 2054) No medical records (n = 452)
Non-Hispanic white Non-Hispanic black Hispanic Other Non-Hispanic white Non-Hispanic black Hispanic Other
Total 1812 (88) 114 (6) 69 (3) 58 (3) 349 (77) 67 (15) 20 (4) 16 (4)
Age at diagnosis, yearsc
35–49 229 (13) 17 (15) 15 (22) 12 (21) 51 (15) 18 (27) 2 (11) 2 (13)
50–54 247 (14) 12 (11) 12 (17) 9 (16) 42 (13) 13 (20) 5 (26) 1 (6)
55–59 329 (18) 25 (22) 8 (12) 9 (16) 68 (20) 14 (21) 2 (11) 6 (38)
60–64 334 (18) 24 (21) 15 (22) 14 (24) 61 (18) 5 (8) 4 (21) 2 (13)
≥ 65 673 (37) 36 (32) 19 (28) 14 (24) 114 (34) 16 (24) 6 (32) 5 (31)
Family history of breast cancer, number of relativesb
1 1149 (63) 75 (66) 46 (67) 38 (66) 224 (64) 49 (73) 14 (70) 10 (63)
2 567 (31) 28 (25) 19 (28) 18 (31) 113 (32) 17 (25) 4 (20) 4 (25)
≥ 3 96 (5) 11 (10) 4 (6) 2 (3) 12 (3) 1 (1) 2 (10) 2 (13)
Menopausal status at diagnosisc
Premenopausal 374 (21) 28 (25) 21 (30) 15 (26) 72 (21) 26 (39) 4 (20) 5 (31)
Postmenopausal 1427 (79) 86 (75) 48 (70) 42 (74) 271 (79) 41 (61) 16 (80) 11 (69)
Educationc
High school or less 253 (14) 8 (7) 10 (14) 10 (17) 54 (15) 6 (9) 6 (30) 4 (25)
Some college, no degree 313 (17) 20 (18) 14 (20) 13 (22) 62 (18) 17 (25) 2 (10) 7 (44)
Associate/ technical degree 238 (13) 18 (16) 10 (14) 6 (10) 53 (15) 17 (25) 3 (15) 1 (6)
Bachelor’s degree 509 (28) 32 (28) 21 (30) 20 (34) 94 (27) 17 (25) 5 (25) 1 (6)
Graduate degree 499 (28) 36 (32) 14 (20) 9 (16) 86 (25) 10 (15) 4 (20) 3 (19)
Marital statusc
Legally or living as married 1418 (78) 52 (46) 43 (62) 46 (79) 248 (71) 41 (61) 14 (70) 12 (75)
Not legally or living as married 394 (22) 62 (54) 26 (38) 12 (21) 101 (29) 26 (39) 6 (30) 4 (25)
Household incomec
< $50,000 381 (22) 33 (30) 31 (45) 17 (29) 91 (28) 14 (22) 9 (45) 7 (47)
$50,000–$99,999 705 (41) 54 (49) 21 (30) 22 (38) 117 (36) 29 (45) 8 (40) 4 (27)
≥ $100,000 643 (37) 24 (22) 17 (25) 19 (33) 114 (35) 22 (34) 3 (15) 4 (27)
aData are reported as number (percentage) of women. Totals may not always equal 100% because of rounding
bIncludes sisters (full and half), mother, and daughters
cMissing: n = 15 (age at diagnosis); n = 18 (menopausal status); n = 1 (race/ethnicity, education, marital status); n = 117 (household income)
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reflecting the lower incidence of these subtypes. Hor-
mone receptor (ER and PR) positive and HER2 negative
self-reports were nearly certain to be confirmed by med-
ical records when available whereas ER negative, PR
negative, and HER2 positive self-reports had lower PPVs
(83.0%, 71.6%, and 66.1% respectively). Even though
PPVs were high for several breast cancer characteristics,
over 10% of women did not provide self-reported data
for ductal or lobular type or for ER status, and over 20%
of women did not provide self-reported data for PR or
HER2 status.
We further explored whether there were differences
in reporting of breast cancer characteristics according
to race/ethnicity and age at diagnosis. Based on medical
records, breast cancer characteristics were fairly similar
across race/ethnicity groups except that non-Hispanic
black women had slightly lower proportions of invasive
and lobular only breast cancer and higher proportions
of invasive ER negative and PR negative disease than
non-Hispanic whites (Table 3). PPVs were fairly similar
across race/ethnicity groups, with the exception of
lobular only and ER negative self-reports for which
PPVs were higher among non-Hispanic white women, al-
though estimates for lobular only breast cancer were
based on small numbers for minorities. PPVs were espe-
cially low for Hispanic women for in situ disease, stage 0
(i.e. represents in situ disease), and invasive ER negative
disease. Even though the PPV for in situ disease among
non-Hispanic blacks was similar to non-Hispanic whites,
a greater proportion of non-Hispanic black women self-
reported in situ cancer (52%) than did non-Hispanic white
women (36%).
The PPV of self-reported invasive breast cancer did
not vary with age at diagnosis, but there was an inverse
relationship between age and the PPV for in situ dis-
ease, with the lowest PPV for in situ breast cancer
among women age 65 years or older at diagnosis
(51.3%) (Table 4). A similar inverse pattern for PPVs for
stage 0 disease (i.e. represents in situ cancer) according
to age at diagnosis was observed. In addition, for stage
II and stage III/IV breast cancer, the PPVs were the
lowest for the oldest women. We also calculated PPVs
stratified by education and the number of relatives with
breast cancer and observed no differences (data not
shown).
The self-reported breast cancer follow-up question-
naire was revised over time to address a concern that
some women might be mistaking “invasive” for meta-
static spread. Completion of each breast cancer follow-
up questionnaire version for the medically confirmed
cases in this analysis was: version 1 (n = 745, 37%),
version 2 (n = 235, 12%), version 3 (n = 690, 34%), and
version 4 (n = 338, 17%). In addition to providing
detailed definitions of terms in versions 3 and 4, other
changes included re-ordering of questions to better
separate invasive from in situ disease. We further
evaluated whether differences in how invasiveness
questions were asked across breast cancer follow-up
questionnaire versions impacted agreement. Agreement
for invasive and in situ breast cancer was generally con-
sistent across questionnaire versions, with the excep-
tion of the first version for which the PPV for in situ
breast cancer was 60% versus 70–71% in later versions.
Table 2 Positive Predictive Values (PPV) of self-reported breast
cancer characteristics, Sister Study 2003-2014a
Breast cancer
characteristic
Medical
record (%)b
Self-reportb PPV (%)
Invasiveness
Invasive 1533 (76) 1191 (63) 99.3
In situ 472 (24) 711 (37) 64.2
Unknown 3 106
Locationc
Ductal (any) 1804 (90) 1562 (88) 98.9
Lobular only 190 (10) 215 (12) 75.7
Unknown 9 226
Stage
0 471 (24) 563 (32) 71.1
I 1035 (52) 712 (41) 92.1
II 380 (19) 352 (20) 67.9
III/IV 117 (6) 128 (7) 71.1
Unknown 5 253
Among medically confirmed invasive cases:d
ER
Positive 1277 (85) 1104 (83) 99.1
Negative 217 (15) 234 (17) 83.0
Unknown 39 195
PR
Positive 1081 (73) 643 (62) 98.9
Negative 404 (27) 402 (38) 71.6
Unknown 48 488
HER2
Positive 167 (12) 232 (22) 66.1
Negative 1271 (88) 845 (78) 99.1
Unknown 95 456
Abbreviation: ER estrogen receptor, PR progesterone receptor, HER2 human
epidermal growth factor receptor 2, PPV positive predictive value
aExcludes 43 who did not complete the questionnaire about breast cancer
characteristics and 3 who reported on a different breast cancer event than the
one abstracted from her medical records
bData are reported as number (percentage) of women. Totals may not always
equal 100% because of rounding
cExcludes 5 cases that are not of ductal or lobular origin (phyllodes tumors)
dER, PR, and HER2 analyses are restricted to 1533 cases confirmed as invasive
breast cancer by medical records
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The first version asked women to provide invasive or in
situ and other characteristics for each breast tumor
found at the initial breast cancer diagnosis while later
versions focused on overall characteristics of the initial
diagnosis and hence added an option for “both” inva-
sive and in situ. We also evaluated whether differences
in staging assessment across versions of the question-
naire impacted the accuracy of self-reported cancer
stage. PPV for stage 0 disease was substantially better
for the two most recent versions of the breast can-
cer follow-up questionnaire where summary stage was
asked (85.7%) than for the two earlier questionnaire
versions where a TNM staging algorithm was applied
(61.9%) to self-reported tumor details. However, the op-
posite pattern existed for the PPVs for stage II (63.4%
vs. 73.4%) and stage III/IV disease (61.3% vs. 80.3%).
We explored whether the lower positive predictive
values for self-reported stages of II and greater in the
more recent questionnaire versions were due to a discrep-
ancy between what the clinicians were telling women
about stage and what could be calculated from the med-
ical record-abstracted TNM variables. In order to address
this issue, we conducted a sub-study of approximately 250
medical record-abstracted invasive breast cancers with
Table 3 Positive Predictive Values (PPV) of self-reported breast cancer characteristics stratified by race/ethnicity, Sister Study 2003-2014a
Non-Hispanic white (n = 1774) Non-Hispanic black (n = 111) Hispanic (n = 66)
Breast cancer characteristic Medical
record (%)b
Self-report (%)b PPV (%) Medical
record (%)b
Self-report (%)b PPV (%) Medical
record (%)b
Self-report (%)b PPV (%)
Invasiveness
Invasive 1360 (77) 1074 (64) 99.3 77 (70) 48 (48) 100 51 (77) 32 (53) 100
In situ 412 (23) 615 (36) 65.3 33 (30) 51 (52) 62.7 15 (23) 28 (47) 46.4
Unknown 2 85 1 12 0 6
Locationc
Ductal (any) 1586 (90) 1380 (88) 99.0 106 (96) 87 (92) 100 60 (91) 47 (85) 97.9
Lobular only 175 (10) 196 (12) 77.0 4 (4) 8 (8) 42.9 6 (9) 8 (15) 62.5
Unknown 8 193 1 16 0 11
Stage
0 411 (23) 488 (31) 72.2 33 (30) 39 (40) 71.8 15 (23) 20 (38) 50.0
I 924 (52) 654 (42) 92.6 47 (43) 31 (32) 83.3 34 (52) 15 (29) 86.7
II 333 (19) 317 (20) 68.8 23 (21) 17 (17) 64.7 15 (23) 10 (19) 60.0
III/IV 102 (6) 102 (7) 75.5 7 (6) 11 (11) 54.5 2 (3) 7 (13) 28.6
Unknown 4 213 1 13 0 14
Among medically confirmed invasive cases:d
ER
Positive 1147 (87) 1011 (84) 99.5 55 (71) 38 (64) 94.7 43 (90) 31 (79) 96.8
Negative 179 (13) 196 (16) 85.6 22 (29) 21 (36) 71.4 5 (10) 8 (21) 50.0
Unknown 34 153 0 18 3 12
PR
Positive 983 (75) 602 (64) 99.2 42 (55) 18 (40) 94.4 29 (62) 13 (45) 100
Negative 335 (25) 342 (36) 71.4 35 (45) 27 (60) 74.1 18 (38) 16 (55) 66.7
Unknown 42 416 0 32 4 22
HER2
Positive 144 (11) 203 (21) 64.7 6 (8) 11 (24) 54.5 9 (19) 7 (26) 100
Negative 1129 (89) 772 (79) 99.1 69 (92) 35 (76) 100 39 (81) 20 (74) 100
Unknown 87 385 2 31 3 24
Abbreviation: PPV positive predictive value, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
aExcludes 43 who did not complete the questionnaire about breast cancer characteristics and 3 who reported on a different breast cancer event than the one
abstracted from her medical records and excludes 56 who reported other race/ethnicity and 1 with missing data for race/ethnicity
bData are reported as number (percentage) of women. Totals may not always equal 100% because of rounding
cExcludes 5 cases that are not of ductal or lobular origin (phyllodes tumors)
dER, PR, and HER2 analyses are restricted to 1360 non-Hispanic white, 77 non-Hispanic black, and 51 Hispanic cases confirmed as invasive breast cancer by
medical records
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oversampling for minorities and those with advanced
stage disease. We abstracted clinician stages noted within
the medical records and compared this data with medical
record stages calculated by applying the TNM staging al-
gorithm. Clinician stage was generally consistent with the
stage calculated by applying the TNM staging algorithm
to the medical record data (data not shown).
Discussion
In our sample, self-reported breast cancer had over 99%
probability of being confirmed by medical record. When
we evaluated breast cancer type, we found that the high
confirmation of self-reported breast cancer with medical
records was limited to invasive breast cancer, with no vari-
ation by race/ethnicity or age at diagnosis. Women who
self-reported in situ breast cancer often were found to
have invasive cancer, and the PPV of in situ cancer was es-
pecially low for older (≥ 65 years at diagnosis) and His-
panic women.
We also found that non-Hispanic blacks had the highest
proportion of self-reported in situ disease but agreed to
provide medical records less often. Given the low PPV of
self-reported in situ disease, substantial misclassification
could result from reliance on self-reported information.
Table 4 Positive Predictive Values (PPV) of self-reported breast cancer characteristics stratified by age at diagnosis, Sister Study 2003-
2014a
35–54 (n = 536) 55–64 (n = 744) ≥65 (n = 728)
Breast cancer
characteristic
Medical
record (%)b
Self-report
(%)b
PPV
(%)
Medical
record (%)b
Self-report
(%)b
PPV
(%)
Medical
record (%)b
Self-report
(%)b
PPV
(%)
Invasiveness
Invasive 396 (74) 340 (65) 99.4 554 (75) 448 (63) 99.3 583 (80) 403 (60) 99.3
In situ 139 (26) 181 (35) 75.1 188 (25) 263 (37) 69.7 145 (20) 267 (40) 51.3
Unknown 1 15 2 33 0 58
Locationc
Ductal (any) 467 (88) 426 (85) 98.6 669 (90) 586 (88) 99.1 668 (92) 550 (90) 98.9
Lobular only 64 (12) 76 (15) 76.0 71 (10) 78 (12) 76.9 55 (8) 61 (10) 73.8
Unknown 3 32 2 78 4 116
Stage
0 139 (26) 159 (32) 78.0 187 (25) 214 (33) 75.5 145 (20) 190 (31) 60.5
I 241 (45) 183 (37) 92.8 367 (50) 258 (39) 91.9 427 (59) 271 (45) 91.9
II 116 (22) 114 (23) 71.1 141 (19) 134 (20) 67.2 123 (17) 104 (17) 65.4
III/IV 38 (7) 37 (8) 75.7 46 (6) 52 (8) 73.1 33 (5) 39 (6) 64.1
Unknown 2 43 3 86 0 124
Among medically confirmed invasive cases:d
ER
Positive 322 (84) 305 (81) 98.7 454 (83) 406 (82) 99.0 501 (89) 393 (85) 99.5
Negative 63 (16) 73 (19) 82.6 90 (17) 92 (18) 87.6 64 (11) 69 (15) 77.3
Unknown 11 18 10 56 18 121
PR
Positive 293 (76) 207 (65) 99.5 375 (69) 213 (57) 99.1 413 (74) 223 (64) 98.2
Negative 91 (24) 112 (35) 69.7 166 (31) 163 (43) 72.0 147 (26) 127 (36) 73.0
Unknown 12 77 13 178 23 233
HER2
Positive 49 (13) 64 (20) 71.7 65 (12) 90 (23) 67.0 53 (10) 78 (22) 60.0
Negative 324 (87) 263 (80) 98.0 458 (88) 310 (78) 100 490 (90) 272 (78) 99.2
Unknown 23 69 31 154 40 233
Abbreviation: PPV positive predictive value, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
aExcludes 43 who did not complete the questionnaire about breast cancer characteristics and 3 who reported on a different breast cancer event than the one
abstracted from her medical records
bData are reported as number (percentage) of women. Totals may not always equal 100% because of rounding
cExcludes 5 cases that are not of ductal or lobular origin (phyllodes tumors)
dER, PR, and HER2 analyses are restricted to 1533 cases (35–54: n = 396; 55–64: n = 554; ≥65: n = 583) confirmed as invasive breast cancer by medical records
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Therefore, improved questionnaire formats including
understandable definitions of breast cancer subtypes and
strategies to enhance agreement to medical record re-
trieval are needed. In the Sister Study, for example, in
addition to adding definitions to explain in situ disease,
we added study “advocates” who work to develop personal
relationships with participants and encourage their study
participation. We have also developed study materials that
included endorsements from breast cancer professionals
noting both the importance of medical records and their
willingness to provide them, to address a concern that
some women, especially minorities, may have been reluc-
tant to impose on clinicians. These strategies appear to
have increased willingness to authorize access to medical
records, but it is too soon to determine the overall impact
on participation in medical record retrieval activities. The
tendency of some women to report their invasive breast
cancer as in situ also points to the need for research
evaluating whether health care providers are adequately
relaying information to women about their breast cancer
diagnosis, especially for minority groups where health care
disparities are known to exist [11].
That women of all race/ethnicity and age groups with
breast cancer can accurately report ductal cancers is re-
assuring for epidemiologic research but not surprising
given that ductal breast cancer represented at least 85%
of all breast cancers according to the medical record.
Lobular only cancer, which is far less common, had
lower positive predictive values that varied somewhat by
race/ethnicity, with non-Hispanic black women having
the lowest PPV. However, PPV is sensitive to disease
prevalence as it is often lower when disease prevalence
is also lower.
The low PPV for ER negative invasive breast cancer
may reflect a lack of patient understanding of their
disease and not simply the lower overall incidence for
this subtype. This raises concern for both patient com-
pliance with treatments and interpretation of epidemi-
ology studies that rely on self-reported data, especially
for studies designed to identify distinct preventable risk
factors for ER negative invasive breast cancer, which has
a higher case-fatality [14, 15]. McCarthy, et al. found
moderate agreement between self-report and state can-
cer registry data for ER/PR status, and agreement was
high after excluding over 20% of women with missing
data for self-reports [7]. Consistent with our study, how-
ever, they found greater inaccuracy among non-white
women with ER/PR negative disease according to the
medical data [7]. Women may be especially aware of
their hormone receptor positive status due to the preva-
lent use of oral endocrine therapies such as tamoxifen
[16]. However, HER2 positive self-reports had a much
lower accuracy than HER2 negative self-reports, reflect-
ing the lower prevalence of HER2 positive disease overall
and possibly the use of targeted infusion therapy that
acts as a HER2 inhibitor [17], but may not be easily sep-
arated from chemotherapy from the patient perspective.
Further research is needed to clarify whether reasons for
lower positive predictive values are that women are not
having detailed conversations with their physician or
they do not sufficiently understand the parameters of
their diagnosis.
Missing data may also have impacted our results as
over 10% of women did not provide self-reported data
for ER status and over 20% of women did not provide
data on PR or HER2 status. The proportion with missing
self-reports did not vary by hormone receptor status
from medical records; however, women with medical
record-abstracted HER2 negative disease were more
likely to have missing self-reports than those who were
HER2 positive. We restricted our hormone receptor and
HER2 analyses to medical record-abstracted invasive
breast cancer because assays are not consistently done
for in situ disease.
The majority of women in the Sister Study had stage
I breast cancer, with positive predictive values over 80%
for all race/ethnicity and age groups. Other invasive
stages had lower positive predictive values, and older
women especially tended to misreport higher stage
disease. We had speculated if it was possible that clini-
cians were providing women with summary stage infor-
mation that was inconsistent with the TNM staging
algorithm we applied to data abstracted from the med-
ical record. However, based on results from our sub-
study of approximately 250 medical record-abstracted
invasive breast cancers, it is unlikely that the lower
positive predictive values were due to clinicians provid-
ing women with incorrect staging information. Yet de-
pending on the timing of medical records available
relative to the initial diagnosis and the extent of records
provided, there could be more than one clinician-
reported stage, and these were sometimes discordant.
Furthermore, we had no way to verify whether what cli-
nicians reported to the patient matched what they re-
corded in the medical record. Use of the TNM staging
algorithm rather than clinician reports for assessing
stage from medical records provided a standard ap-
proach across medical records that is not impacted by
change over time or by clinician practices such as use
of different editions of the American Joint Committee
on Cancer (AJCC) TNM Breast Cancer Staging
algorithm.
Strengths of this study include the extensive data col-
lection on breast cancer diagnostic characteristics and
the large number of breast cancer cases to evaluate
medical record confirmation of self-reports. However,
smaller number of Hispanic breast cancer cases limited
race/ethnicity comparisons. Given that Sister Study
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participants have a family history of breast cancer and
voluntarily joined a study about risk factors for devel-
oping breast cancer, it might be expected that partici-
pants would be more knowledgeable about breast
cancer, and thus better able to accurately self-report
characteristics of their own subsequent diagnosis than
women diagnosed with breast cancer in the general
population. Nevertheless, we still found that the accur-
acy of self-reporting tumor characteristics such as in
situ type as well as other less common breast cancer
subtypes such as lobular only, hormone receptor nega-
tive, and HER2 positive breast cancer was somewhat
problematic.
Conclusions
For epidemiologic studies evaluating risk factors for
breast cancer subtypes, special attention in question-
naire materials and messaging is needed as well as
increased efforts to build trust with research partici-
pants to ensure that all sociodemographic groups are
well represented with medical records to verify breast
cancer characteristics. Nevertheless, we found a high
accuracy of self-reports for overall breast cancer and
more common subtypes, which suggests that self-
reports are a reasonable substitute in studies with
these outcomes. Further research should focus on ex-
ploring whether inaccuracies in less common self-
reported breast cancer subtypes and diagnostic staging
are due to women’s poor understanding of what health
care providers tell them or to their being given incom-
plete information about their breast cancer diagnosis.
This information could better guide health care pro-
viders on how to best communicate key diagnostic in-
formation to their patients. Comprehension of breast
cancer diagnostic features is important for women to
be more active with their health care, leading to better
decision making and possibly improved treatment
adherence.
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